Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
about
New perspectives in glioblastoma antiangiogenic therapyDeferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferationCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Recurrent malignant gliomas.Deregulated proliferation and differentiation in brain tumors.The mTOR signaling pathway as a treatment target for intracranial neoplasmsPI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.Standards of care and novel approaches in the management of glioblastoma multiforme.Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.Use of bevacizumab in recurrent glioblastoma.Toward precision medicine in glioblastoma: the promise and the challenges.Glioblastoma targeted therapy: updated approaches from recent biological insights.Investigational new drugs for brain cancer.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma.Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.Trends in Malignant Glioma Monoclonal Antibody Therapy.
P2860
Q26746028-AC02A5A5-DAB8-46EC-9EE6-B95DD4A62E7DQ33616632-507DEBD5-791F-4EF3-9F68-9E8340789374Q34113332-6BD93C60-040E-4359-B293-78A55D9D79E5Q34437996-BD74A05C-7B32-4251-BBA5-71D98AF349BBQ34438507-DF1320A2-24F5-4E7A-9300-1A2AF84E1F3BQ34859989-A74FF991-CBE8-41E4-93FF-4EED58EDB3FBQ34886859-70D51ADA-B807-4A7F-8031-2C81A1C57889Q36086507-65A37B6B-19AF-448A-9162-363697E72CDCQ36918102-BFC13A16-F614-417A-9CF4-BE594B8D2B8BQ37525881-7D9CB985-A5C4-41D4-BB45-8154D067A0FEQ37725493-D2B9B105-9A5F-4F4B-9AAC-734FE926095EQ38438668-1F27677A-66CD-4DA1-B84F-0B065D1E89EAQ38454659-413486BE-BF64-4C8D-B629-4A90F43117AAQ38597700-C60A6824-C146-401F-A2C7-80CEC18FB6E9Q38832510-EF06F576-8E18-4C02-BA19-CC37E137403CQ39022941-AEC3543F-6FDF-491B-BF06-43B954658E78Q39436924-7BB7187D-AD95-41D3-AB89-767EA0841833Q43236112-545E6AAA-873D-49DD-ABCB-FAE5384E23E9Q47219387-37649DC0-E38B-4343-A69A-7559D4E740F7Q47436703-0F549A7D-9466-40A2-95F3-570B552A2C26Q54942652-E5CB0165-C227-4D39-B2E1-9A0D50AB564C
P2860
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@ast
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@en
type
label
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@ast
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@en
prefLabel
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@ast
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@en
P2093
P1433
P1476
Phase II study of bevacizumab ...... rrent glioblastoma multiforme.
@en
P2093
Benedikte Hasselbalch
Hans Skovgaard Poulsen
Morten Sorensen
Tine Bernhardtsen Gaziel
Ulrik Lassen
P304
P407
P577
2013-04-01T00:00:00Z